UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS

The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.

EGFR KRAS BRCA ALK
Breast cancer x x x
Renal cell carinoma x
Ovarian cancer x
Prostate cancer x
Pancreatic cancer x x
Colorectal cancer x x x
Non-small-cell lung cancer x x x
Head and neck cancer x
Thyroid carcinoma x
Small-cell lung cancer x
Rare tumors x x

FIRST-LINE DRUG-TREATABLE EGFR POPULATIONS

Breast cancer

Non-small-cell lung cancer

Small-cell lung cancer

Squamous cell carcinoma of the head and neck

Colorectal cancer

EPIDEMIOLOGY IS THE FOUNDATION OF MARKET FORECASTING AT ALL PHASES OF PRODUCT DEVELOPMENT AND STRATEGY

You need biomarker epidemiology data that you can trust in order to:

  • Complete biomarker-driven market-sizing assessments based on patient population sizes and patient flows.
  • Build the foundation of a market forecast for strategic planning for biomarker-targeting for new and existing assets.
  • Understand how the patient populations for certain biomarkers will evolve over time.
  • Answer any question you may have about specific subpopulations, biomarkers, and the impact of new studies.

Table of contents

  • EGFR - Epidemiology - Mature Markets Data

Author(s): Abey John, MPH

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.